Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M. Craig TJ, et al. Among authors: jacobs js, jacobs i. Lancet. 2023 Apr 1;401(10382):1079-1090. doi: 10.1016/S0140-6736(23)00350-1. Epub 2023 Feb 28. Lancet. 2023. PMID: 36868261 Clinical Trial.
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.
Craig T, Lumry W, Cicardi M, Zuraw B, Bernstein JA, Anderson J, Jacobs J, Riedl MA, Manning ME, Banerji A, Gower RG, Caballero T, Farkas H, Feuersenger H, Jacobs I, Machnig T, Longhurst H; COMPACT Investigators. Craig T, et al. Among authors: jacobs j, jacobs i. J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):2035-2038. doi: 10.1016/j.jaip.2019.01.007. Epub 2019 Jan 17. J Allergy Clin Immunol Pract. 2019. PMID: 30660873 Free article. Clinical Trial. No abstract available.
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T, Zuraw B, Longhurst H, Cicardi M, Bork K, Grattan C, Katelaris C, Sussman G, Keith PK, Yang W, Hébert J, Hanzlikova J, Staubach-Renz P, Martinez-Saguer I, Magerl M, Aygören-Pürsün E, Farkas H, Reshef A, Kivity S, Neri S, Crisan I, Caballero T, Baeza ML, Hernandez MD, Li H, Lumry W, Bernstein JA, Hussain I, Anderson J, Schwartz LB, Jacobs J, Manning M, Levy D, Riedl M, Christiansen S, Feuersenger H, Pragst I, Mycroft S, Pawaskar D, Jacobs I; COMPACT Investigators. Craig T, et al. Among authors: jacobs j, jacobs i. J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):1793-1802.e2. doi: 10.1016/j.jaip.2019.01.054. Epub 2019 Feb 15. J Allergy Clin Immunol Pract. 2019. PMID: 30772477 Free article. Clinical Trial.
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
Bernstein JA, Schwartz L, Yang W, Baker J, Anderson J, Farkas H, Aygören-Pürsün E, Bygum A, Jacobs I, Feuersenger H, Pragst I, Riedl MA. Bernstein JA, et al. Among authors: jacobs i. Ann Allergy Asthma Immunol. 2020 Sep;125(3):334-340.e1. doi: 10.1016/j.anai.2020.05.015. Epub 2020 May 20. Ann Allergy Asthma Immunol. 2020. PMID: 32445670 Free article. Clinical Trial.
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Pawaskar D, Jacobs I, Pragst I, Doyle MK. Craig T, et al. Among authors: jacobs js, jacobs i. Lancet. 2022 Mar 5;399(10328):945-955. doi: 10.1016/S0140-6736(21)02225-X. Epub 2022 Feb 24. Lancet. 2022. PMID: 35219377
Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, Jacobs I, Lawo JP, Glassman F, Akama H, Hide M, Ohsawa I. Fukuda T, et al. Among authors: jacobs i. Allergol Int. 2023 Jul;72(3):451-457. doi: 10.1016/j.alit.2023.02.002. Epub 2023 Feb 28. Allergol Int. 2023. PMID: 36858856 Free article. Clinical Trial.
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Craig TJ, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Alexandru Bica M, Jacobs I, Pragst I, Magerl M. Craig TJ, et al. Among authors: jacobs i. Lancet Haematol. 2024 May 3:S2352-3026(24)00081-4. doi: 10.1016/S2352-3026(24)00081-4. Online ahead of print. Lancet Haematol. 2024. PMID: 38710185
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, Barazani-Brutman T, Voigt C, Jacobs I, Wuerfel T, Santagostino E. Martinowitz U, et al. Among authors: jacobs i. Haemophilia. 2015 Nov;21(6):784-90. doi: 10.1111/hae.12721. Epub 2015 May 20. Haemophilia. 2015. PMID: 25990590 Free PMC article. Clinical Trial.
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E. Négrier C, et al. Among authors: jacobs i. Haemophilia. 2016 Jul;22(4):e259-66. doi: 10.1111/hae.12972. Epub 2016 Jun 22. Haemophilia. 2016. PMID: 27333467 Clinical Trial.
936 results